Omeros Corporation (OMER)
OMER Stock Price Chart
Explore Omeros Corporation interactive price chart. Choose custom timeframes to analyze OMER price movements and trends.
OMER Company Profile
Discover essential business fundamentals and corporate details for Omeros Corporation (OMER) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2009
Employees
202.00
Website
https://www.omeros.comCEO
Gregory A. Demopulos
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Financial Timeline
Browse a chronological timeline of Omeros Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.58.
Earnings released on 14 Aug 2025
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%.
Earnings released on 15 May 2025
EPS came in at -$0.65 falling short of the estimated -$0.57 by -14.04%.
Earnings released on 31 Mar 2025
EPS came in at -$0.63 surpassing the estimated -$0.78 by +19.23%, while revenue for the quarter reached $412.00K .
Earnings released on 13 Nov 2024
EPS came in at -$0.64 surpassing the estimated -$0.70 by +8.57%.
Earnings released on 7 Aug 2024
EPS came in at -$1.12 surpassing the estimated -$1.14 by +1.75%.
Earnings released on 15 May 2024
EPS came in at -$0.74 falling short of the estimated -$0.58 by -27.59%.
Earnings released on 1 Apr 2024
EPS came in at -$0.63 falling short of the estimated -$0.56 by -12.50%, while revenue for the quarter reached $1.37M .
Earnings released on 9 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.62 by -32.26%.
Earnings released on 9 Aug 2023
EPS came in at -$0.70 falling short of the estimated -$0.60 by -16.67%.
Earnings released on 9 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.55 by -14.55%.
Earnings released on 13 Mar 2023
EPS came in at -$0.73 falling short of the estimated -$0.57 by -28.07%.
Earnings released on 9 Nov 2022
EPS came in at -$0.87 falling short of the estimated -$0.61 by -42.62%.
Earnings released on 9 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$0.68 by +11.76%, while revenue for the quarter reached $10.10M .
Earnings released on 10 May 2022
EPS came in at -$0.56 surpassing the estimated -$0.74 by +24.32%, while revenue for the quarter reached $27.70M , beating expectations by +171.24%.
Earnings released on 1 Mar 2022
EPS came in at -$0.37 falling short of the estimated -$0.30 by -23.33%, while revenue for the quarter reached -$79.89M , missing expectations by -219.38%.
Earnings released on 9 Nov 2021
EPS came in at -$0.26 surpassing the estimated -$0.45 by +42.22%, while revenue for the quarter reached $30.00M , missing expectations by -0.48%.
Earnings released on 9 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%, while revenue for the quarter reached $28.82M , beating expectations by +25.37%.
Earnings released on 10 May 2021
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%, while revenue for the quarter reached $21.06M , meeting expectations.
Earnings released on 1 Mar 2021
EPS came in at -$0.54 surpassing the estimated -$0.64 by +15.62%, while revenue for the quarter reached $10.63M .
Earnings released on 9 Nov 2020
EPS came in at -$0.34 surpassing the estimated -$0.51 by +33.33%, while revenue for the quarter reached $26.11M , beating expectations by +8.93%.
OMER Stock Performance
Access detailed OMER performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.